Image Place holder

Ricardo LB Costa, MD, MSc

Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt Cancer Center at International Plaza
Moffitt McKinley Outpatient Center

Cancer Types Treated: Invasive Ductal Carcinoma , Triple Negative Breast Cancer , Breast Cancer, Ductal Carcinoma In Situ , Inflammatory Breast Cancer

Dr. Costa is a Medical Oncologist at the Department of Breast Oncology at Moffitt Cancer Center in the Clinical Investigator Track since 2017. In 2011, Dr. Costa completed a Master Degree in Clinical Research at University of Pittsburgh and Clinical Fellowship Training at Allegheny General Hospital, Pittsburgh, Pennsylvania. Dr. Costa was an Instructor at the Developmental Therapeutics Program at Northwestern University, Chicago, where he developed early phase clinical trials for the treatment of breast cancer. He has already authored and co-authored over 40 scientific manuscripts. His current research projects are focused on the development of Targeted Agents and Immune Therapies, including new vaccines and antibodies, for the treatment of breast cancer. He is currently a Principal Investigator of clinical trials at Moffitt Cancer Center and treats women with all stages of breast cancer.

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine


  • Drexel of Pittsburgh Allegheny General Hospital - Hematology/Oncology
  • Northwestern University Feinberg School of Medicine - Developmental Therapeutics


  • East Tenessee State University - Internal Medicine

Medical School:

  • Federal University of Pernambuco, Brazil - MD
Participating Trials

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Condition: Breast
Intervention: Not Applicable

I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition: Breast

Phase II Open-Label, Randomized Study of PARP inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Olaparib (Lynparza)

A Phase Ib/II, Open-Label, Multicenter,Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab; Cobimetinib; Eribulin Mesylate; Gemzar (gemcitabine); Ipatasertib; Not Applicable; RO6874281; SGN-LIV1A; Selicrelumab; Xeloda (capecitabine); capecitabine; gemcitabine

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Condition: Breast
Intervention: Carvedilol; Not Applicable

A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination with Intravenous Pembrolizumab Therapy in Patients with Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); tavo-EP

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses and Treatment Intensification of a Vaccine-Based Immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for Advanced Non-Small Cell Lung Cancer and Metastatic Triple-Negative Breast Cancer
Condition: Breast
Intervention: AdC68; CP-675,206 (tremelimumab); PF-06801591; pDNA; tremelimumab

Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Condition: Breast
Intervention: BMS-936558 (Nivolumab); Nivolumab

A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)

A Phase II Trial With Safety Run-In Of Neoadjuvant Therapy With An Aromatase Inhibitor In Combination With Durvalumab (Medi4736) In Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer
Condition: Breast
Intervention: AMP-514 (Durvalumab); Anastrozole; Arimadex (Anastrozole); Aromasin (Exemestane); Durvalumab; Exemestane; Femara (Letrozole); Letrozole; MEDI4736 (Durvalumab)

A Phase 1, Open-label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of ARV-471 in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer, Who Have Received Prior Hormonal Therapy and Chemotherapy in the Locally Advanced/Metastatic Setting
Condition: Breast
Intervention: ARV-471

A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
Condition: Breast
Intervention: DC1 Vaccine; Herceptin (Trastuzumab); Paraplatin (carboplatin); Pertuzumab; Taxotere (docetaxel); Trastuzumab; carboplatin; docetaxel; rhuMAb HER2 (Trastuzumab)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Carneiro BA, Konda B, Costa RB, Costa RLB, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ. Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial. J Clin Endocrinol Metab. 2019 Jul. Pubmedid: 31276163.
  • Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B. A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2 breast cancer. Drug Des Devel Ther. 2019 Jan;13:309-316. Pubmedid: 30679903. Pmcid: PMC6338114.
  • Kodumudi KN, Ramamoorthi G, Snyder C, Basu A, Jia Y, Awshah S, Beyer AP, Wiener D, Lam L, Zhang H, Greene MI, Costa RLB, Czerniecki BJ. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. Front Immunol. 2019 Aug;10:1939. Pubmedid: 31475002. Pmcid: PMC6702967.
  • Costa RLB, Gradishar WJ. Do Genomic Assays Provide the Necessary Confidence to De-escalate Adjuvant Therapy?. J Clin Oncol. 2018 Mar;36(8):725-727. Pubmedid: 29373092.
  • Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018 Jun;169(3):397-406. Pubmedid: 29417298.
  • Chae YK, Chiec L, Adney SK, Waitzman J, Costa R, Carneiro B, Matsangou M, Agulnik M, Kopp P, Giles F. Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. Oncotarget. 2018 Jun;9(46):28281-28289. Pubmedid: 29963277. Pmcid: PMC6021337.
  • Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, Laronga C, Hoover SJ, Khakpour N, Costa RLB, Diaz R. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018 Jul;98:48-58. Pubmedid: 29870876.
  • Rossi G, Mu Z, Rademaker A, Austin L, Strickland KS, Lima Barros Costa R, Nagy R, Zagonel V, Taxter TJ, Behdad A, Wehbe FH, Platanias LC, Gradishar W, Cristofanilli M. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. Clin Cancer Res. 2018 Feb;24(3):560-568. Pubmedid: 29180605.
  • Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK. Systematic review and meta-analysis of selected toxicities of approved inhibitors in metastatic non-small cell lung cancer. Oncotarget. 2018 Apr;9(31):22137-22146. Pubmedid: 29774128. Pmcid: PMC5955140.
  • Costa RB, Benson A, Yaghmai V, Costa RLB, Zhou H, Behdad A, Kaplan JB, Sadim M, Talamantes S, Kalyan A. An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. Case Rep Oncol Med. 2018 Apr;2018:6314392. Pubmedid: 29808141. Pmcid: PMC5902098.
  • Reinstein ZZ, Pamarthy S, Sagar V, Costa R, Abdulkadir SA, Giles FJ, Carneiro BA. Overcoming immunosuppression in bone metastases. Crit Rev Oncol Hematol. 2017 Sep;117:114-127. Pubmedid: 28600175.
  • Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017 Sep;8(40):67782-67789. Pubmedid: 28978071. Pmcid: PMC5620211.
  • Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG. A pilot study of cabergoline for the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2017 Oct;165(3):585-592. Pubmedid: 28674764.
  • Pai SG, Carneiro BA, Chae YK, Costa RL, Kalyan A, Shah HA, Helenowski I, Rademaker AW, Mahalingam D, Giles FJ. Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer. J Gastrointest Oncol. 2017 Oct;8(5):858-866. Pubmedid: 29184690. Pmcid: PMC5674261.
  • Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017 May;10(1):101. Pubmedid: 28476164. Pmcid: PMC5420131.
  • Mota JM, Collier KA, Costa RLB, Taxter T, Kalyan A, Leite CA, Chae YK, Giles FJ, Carneiro BA. A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer. Oncotarget. 2017 Jun. Pubmedid: 28645115.
  • Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, Giles FJ. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017 Jun;9:207-213. Pubmedid: 28652812. Pmcid: PMC5476791.
  • Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017 Jun. Pubmedid: 28733528.
  • Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017 Jan;8(5):8910-8920. Pubmedid: 27852042. Pmcid: PMC5352453.
  • Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017 Feb;8(9):16052-16074. Pubmedid: 28030802. Pmcid: PMC5362545.
  • Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M. Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget. 2017 Feb;8(7):12417-12432. Pubmedid: 27926493. Pmcid: PMC5355355.
  • Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives. Cancer Treat Rev. 2017 Dec;61:107-115. Pubmedid: 29125981.
  • Costa RB, Costa R, Kaplan J, Cruz MR, Shah H, Matsangou M, Carneiro B. A Rare Case of Glioblastoma Multiforme with Osseous Metastases. Case Rep Oncol Med. 2017 Dec;2017:2938319. Pubmedid: 29201475. Pmcid: PMC5671696.
  • Costa RLB, Gradishar WJ. Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups. J Glob Oncol. 2017 Aug;3(4):281-284. Pubmedid: 28831435. Pmcid: PMC5560466.
  • Costa RLB, Gradishar WJ. Triple-Negative Breast Cancer: Current Practice and Future Directions. J Oncol Pract. 2017 05;13(5):301-303. Pubmedid: 28489982.
  • Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016 Oct;7(40):65364-65373. Pubmedid: 27588476. Pmcid: PMC5323161.
  • Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol. 2016 Oct. Pubmedid: 27701069.
  • Agulnik M, Costa RL, Milhem M, Rademaker AW, Prunder BC, Daniels D, Rhodes BT, Humphreys C, Abbinanti S, Nye L, Cehic R, Polish A, Vintilescu C, McFarland T, Skubitz K, Robinson S, Okuno S, Van Tine BA. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Ann Oncol. 2016 Oct. Pubmedid: 27771610.
  • Costa R, Carneiro BA, Tavora F, Pai SG, Kaplan JB, Chae YK, Chandra S, Kopp PA, Giles FJ. The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget. 2016 Jul;7(29):46734-46749. Pubmedid: 27102148. Pmcid: PMC5216833.
  • Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, Garrett HB, Agulnik M, Kopp PA, Giles FJ. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther. 2016 Feb;10:873-884. Pubmedid: 27013865. Pmcid: PMC4778792.
  • Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK, Giles FJ. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget. 2016 Aug;7(34):55924-55938. Pubmedid: 27409839. Pmcid: PMC5342462.
  • Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles FJ. Is Personalized Medicine Here?. Oncology (Williston Park). 2016 Apr;30(4):293-303, 307. Pubmedid: 27085327.
  • Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC. Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med. 2014 Jun;2014:952624. Pubmedid: 24900933. Pmcid: PMC4037124.
  • Costa R, Costa R, Bacchi CE, Almeida Filho P. Metastatic insulinoma managed with radiolabeled somatostatin analog. Case Rep Endocrinol. 2014 Jan;2013:252159. Pubmedid: 24455330. Pmcid: PMC3877610.
  • Costa R, Costa R, Costa R. Follicular lymphoma presenting with leptomeningeal disease. Case Rep Hematol. 2014 Dec;2014:767621. Pubmedid: 25544910. Pmcid: PMC4269308.
  • Costa R, Costa RB, Bacchi C, Sarinho F. Adenocarcinoma of the lung presenting with atypical cystic brain lesions. BMJ Case Rep. 2014 Apr;2014. Pubmedid: 24717598. Pmcid: PMC3987522.
  • Costa R, Fazal S, Kaplan RB, Spero J, Costa R. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol. 2013 Mar;32 Suppl 1:S79-S82. Pubmedid: 20556455.
  • Silva Junior GB, Libório AB, Vieira AP, Bem AX, Lopes Filho AS, Figueiredo Filho AC, Guedes AL, Souza JH, Costa CM, Costa R, Daher EF. Evaluation of renal function in sickle cell disease patients in Brazil. Braz J Med Biol Res. 2012 Jul;45(7):652-655. Pubmedid: 22584642. Pmcid: PMC3854265.
  • Barros Costa RL. Targeted therapy: comprehensive review. Am J Hosp Palliat Care. 2009 Apr;26(2):137-146. Pubmedid: 19229068.
  • Costa R, Costa-Filho RB, Talamantes SM, Queiroga F, Campello EC, Cartaxo H, Costa RB. Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review. Case Rep Oncol. 10(2):524-530. Pubmedid: 28690527. Pmcid: PMC5498939.
  • Costa RLB, Costa-Filho RB, Rosa M, Czerniecki BJ. Occult Breast Carcinoma Presenting as Scalp Metastasis. Case Rep Oncol. 10(3):992-997. Pubmedid: 29279704. Pmcid: PMC5731106.